Navigation Links
ViroPharma To Release 2013 First Quarter Financial Results On May 1, 2013
Date:4/25/2013

EXTON, Pa., April 25, 2013 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) first quarter financial results for 2013 are expected to be released on Wednesday, May 1, 2013 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day.  During the conference call, ViroPharma management will discuss the 2013 first quarter financial results, review clinical data and provide development program updates along with other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com.  An audio archive will be available at the same address until May 15, 2013.  To participate in the conference call, please dial (800) 874-4559 (domestic) and (302) 607-2019 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call. 

About ViroPharma Incorporated 
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, cytomegalovirus (CMV), Friedreich's Ataxia, eosinophilic esophagitis (EoE) and adrenal insufficiency. Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures in children and adolescents, adrenal insufficiency and C. difficile-associated diarrhea (CDAD). For full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
2. ViroPharma To Participate In Two Upcoming Healthcare Investor Conferences
3. ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
4. ViroPharma Incorporated Reports Third Quarter 2012 Financial Results
5. ViroPharma To Host Analyst And Investor Seminar On September 21, 2012
6. ViroPharma to Present at the Stifel Nicolaus 2012 Healthcare Conference
7. ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
8. ViroPharma To Release 2012 Second Quarter Financial Results On August 9, 2012
9. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
10. ViroPharma To Participate In The JMP Securities Healthcare Conference
11. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical ... ended December 31, 2016 after market close on ... released later than the previous fiscal year,s results ... and balances of Apicore from the acquisition date ... date meets TSX Venture Exchange listed company requirements. ...
(Date:3/28/2017)... 28, 2017 "Chemotherapy Induced Neutropenia (CIN) – Market Insights, ... and global market trends of the Chemotherapy Induced Neutropenia for the ... Europe ( France , ... , UK) and Japan , as well ... of the world (RoW). The Report covers the therapeutics ...
(Date:3/28/2017)... March 28, 2017  "US Cancer Generics Market ... various indicators and trend analysis related to the ... mainstream pharmaceutical market in US. The report analyzes ... growth on cancer generics drugs in recent years. ... of billions of dollars for various stake holders ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... ... without a referral to new patients from Burnaby, BC. Patients in need of ... mouth reconstruction services, can see the esteemed team at Wall Centre Dental. Drs. ...
(Date:3/29/2017)... ... 2017 , ... Patients interested in receiving quick and effective ... Cameron, with or without a referral. The FASTBRACES system is valued for its ... patient’s case, treatment with the FASTBRACES system could be completed in 120 days ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... continues developing an ANSI-approved, consensus-based American National Standard for Good Manufacturing Practices ... the first ANSI-approved GMP standard for dietary supplements this spring, is hiring ...
(Date:3/29/2017)... ... 29, 2017 , ... Altima Technologies, Inc., the maker of ... center assets and audio-video devices has recently updated its Visio Stencils library with ... and download shapes and stencils from http://www.VisioStencils.com. , New devices were ...
(Date:3/29/2017)... PITTSBURGH, PA (PRWEB) , ... March 29, 2017 ... ... and hassles associated with wearing oral braces. "The rubber bands used in conjunction ... he said, "so I decided to design a way to prevent this problem." ...
Breaking Medicine News(10 mins):